Abctyant BRAF splicing as an alternative mechanism for oncogenic B-Raf activation in thyroid carcinoma

Journal of Pathology

Volumn 217, Issue 5, 2009, Pages 707-715

  Baitei, Essa Y ^a   Zou, Minjing ^a   Al Mohanna, Futwan ^a   Collison, Katharine ^a   Alzahrani, Ali S ^a   Farid, Nadir R ^b   Meyer, Brian ^a   Shi, Yufei ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b The London Endocrine Clinic   (United Kingdom)

Author keywords

BRAF; Mutation; Neoplasia; Splicing variant; Thyroid

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; BRAF PROTEIN, HUMAN; DNA; RNA;

ADULT; ADVANCED CANCER; AMINO TERMINAL SEQUENCE; ANAPLASTIC CARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL STRAIN 3T3; CHO CELL; CONTROLLED STUDY; ENZYME ACTIVATION; FEMALE; GENE ACTIVATION; GENE FREQUENCY; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE; ONCOGENE B RAF; PRIORITY JOURNAL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; SPLICING DEFECT; THYROID CARCINOMA; THYROID FOLLICULAR CARCINOMA; WILD TYPE; CANCER STAGING; GENETICS; METABOLISM; METHODOLOGY; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PAPILLARY CARCINOMA; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SPLICING; THYROID TUMOR;

ADULT; BASE SEQUENCE; CARCINOMA, PAPILLARY; DNA, NEOPLASM; ENZYME ACTIVATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS B-RAF; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA SPLICING; RNA, NEOPLASM; THYROID NEOPLASMS;

EID: 64549083309     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2496     Document Type: Article

References (39)

1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949- 954. Epub 2002 Jun 9.
2. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-867.
3. Dhillon AS, Kolch W. Oncogenic B-Raf mutations: crystal clear at last. Cancer Cell 2004;5:303-304.
4. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see comments]. Cancer 1998;83:2638-2648.
5. Fagin JA. How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 2004;183:249-256.
6. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-1457.
7. Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003;95:625-627.
8. Soares P, Trovisco V, Rocha AS, Lima J, Castro P, Preto A, et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene 2003;22:4578-4580.
9. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393- 4397.
10. Xu X, Quiros RM, Gattuso P, Ain KB, Prinz RA. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res 2003;63:4561-4567.
11. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12:245-262.
12. Knauf JA, Ma X, Smith EP, Zhang L, Mitsutake N, Liao XH, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res 2005;65:4238-4245.
13. Barnier JV, Papin C, Eychene A, Lecoq O, Calothy G. The mouse B-raf gene encodes multiple protein isoforms with tissue-specific expression. JBiol Chem 1995;270:23381-23389.
14. Hmitou I, Druillennec S, Valluet A, Peyssonnaux C, Eychene A. Differential regulation of B-raf isoforms by phosphorylation and autoinhibitory mechanisms. Mol Cell Biol 2007;27:31-43.
15. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al. (eds) Thyroid. In American Joint Committee on Cancer: AJCC Cancer Staging Manual (6th edn). Springer: New York, 2002; 77-87.
16. Shi Y, Zou M, Collison K, Baitei EY, Al-Makhalafi Z, Farid NR, et al. Ribonucleic acid interference targeting S100A4 (Mts1) suppresses tumor growth and metastasis of anaplastic thyroid carcinoma in a mouse model. J Clin Endocrinol Metab 2006;91:2373-2379.
17. Chong H, Guan KL. Regulation of Raf through phosphoryla- tion and N terminus-C terminus interaction. J Biol Chem 2003;278:36269-36276.
18. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxford) 2005;63:588-593.
19. Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, et al.No correlation between BRAFV600E mutation and clinicopatholog- ical features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxford) 2005;63:461-466.
20. Fugazzola L, Mannavola D, Cirello V, Vannucchi G, Muzza M, Vicentini L, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxford) 2004;61:239-243.
21. Puxeddu E, Moretti S, Elisei R, Romei C, Pascucci R, Martinelli M, et al. BRAF(V599E) mutation is the leading genetic event in adult sporadic papillary thyroid carcinomas. J Clin Endocrinol Metab 2004;89:2414-2420.
22. Adeniran AJ, Zhu Z, Gandhi M, Steward DL, Fidler JP, Giordano TJ, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 2006;30:216-222.
23. Nikiforova MN, Kimura ET, Gandhi M, Biddinger PW, Knauf JA, Basolo F, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-5404.
24. Kim J, Giuliano AE, Turner RR, Gaffney RE, Umetani N, Kitago M, et al. Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg 2006;244:799-804.
25. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-821.
26. Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393- 4397.
27. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-6379. Epub 2005 Sep 20.
28. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, Cavaliere A, et al. Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 2006;13:455-464.
29. Trovisco V, Soares P, Preto A, de Castro IV, Lima J, Castro P, et al. Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients' age but not with tumour aggressiveness. Virchows Arch 2005;446:589-595.
30. Trovisco V, Vieira de Castro I, Soares P, Maximo V, Silva P, Magalhaes J, et al. BRAF mutations are associated with some histological types of papillary thyroid carcinoma. J Pathol 2004;202:247-251.
31. Castro P, Rebocho AP, Soares RJ, Magalhaes J, Roque L, Trovisco V, et al. PAX8 -PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab 2006;91:213-220.
32. Schweppe RE, Klopper JP, Korch C, Pugazhenthi U, Benezra M, Knauf JA, et al. DNA profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab 2008;93:4331-4341.
33. Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M, et al. Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 2007;1773:1196-1212.
34. Tran NH, Wu X, Frost JA. B-Raf and Raf-1 are regulated by distinct autoregulatory mechanisms. JBiolChem 2005;280:16244-16253.
35. Harding A, Hsu V, Kornfeld K, Hancock JF. Identification of residues and domains of Raf important for function in vivo and in vitro. JBiolChem 2003;278:45519-45527.
36. Garnett MJ, Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004;6:313-319.
37. Rapp UR, Goldsborough MD, Mark GE, Bonner TI, Groffen J, Reynolds FH Jr, et al. Structure and biological activity of v-raf, a unique oncogene transduced by a retrovirus. Proc Natl Acad Sci U SA 1983;80:4218- 4222.
38. Ciampi R, Knauf JA, Kerler R, Gandhi M, Zhu Z, Nikiforova MN, et al. Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 2005;115:94-101.
39. Garnett MJ, Rana S, Paterson H, Barford D, Marais R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 2005;20:963-969.